about
Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trialDetermining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037)IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder.Comorbidities and race/ethnicity among adults with stimulant use disorders in residential treatment.Self-rated measure of pain frequency, intensity, and burden: psychometric properties of a new instrument for the assessment of painBaseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders.Examining the moderating effect of depressive symptoms on the relation between exercise and self-efficacy during the initiation of regular exercise.STimulant Reduction Intervention using Dosed Exercise (STRIDE) - Description of the Exercise Intervention and Behavioral Program to Ensure Adherence.A Health Education Intervention as the Control Condition in the CTN-0037 STRIDE multi-site exercise trial: Rationale and Description.Evidence-based recommendations for the prescription of exercise for major depressive disorder.Affect Following First Exercise Session as a Predictor of Treatment Response in Depression.Exercise training - A beneficial intervention in the treatment of alcohol use disorders?Psychosocial relationship status and quality as predictors of exercise intervention adherence and substance use outcomes: Results from the STRIDE (CTN-0037) study.Cardiorespiratory fitness and body composition of stimulant users: A baseline analysis of the STRIDE cohort.Promise of Wearable Physical Activity Monitors in Oncology Practice.Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders.An ounce of prevention: A pre-randomization protocol to improve retention in substance use disorder clinical trials.IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY.Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder.Efficacy of exercise in reducing depressive symptoms across 5-HTTLPR genotypes.Response to Stanton, Reaburn, and Rosenbaum.Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?The association of 5-HTTLPR genotype and depressive symptoms is moderated by physical activity.Racial and ethnic differences in treatment outcomes among adults with stimulant use disorders after a dosed exercise intervention.Exercise is an effective treatment for positive valence symptoms in major depression.Effects of depression, metabolic syndrome, and cardiorespiratory fitness on mortality: results from the Cooper Center Longitudinal Study.Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder.Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression.The antidepressive effects of exercise: a meta-analysis of randomized trialsThe Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors
P50
Q35318875-056FFCCE-07FB-4A53-A20C-9C1E29EA178FQ35742096-D972099A-AC34-4549-AB8C-032D98E0518DQ36043319-B6FA5524-8EF4-4E6D-A17F-58D85D8A65EDQ36424056-140318F6-A518-49F5-A2B9-F3A705685FCDQ36659532-90FC7BC4-A9A2-4545-B08B-6AAC7B8622AAQ36757276-C4FFB90B-3DDE-4ECD-B2EB-795A0A620DE3Q36785945-0BFCB4E7-66D3-4E06-99C7-5F973500784BQ36827478-3D12F41A-E850-4A1E-AF78-40C49391EF22Q37692057-510172AD-54C3-4F45-AACE-EAC7C2B310E5Q38105031-6C709872-B3E9-425B-B3AD-DB375599C567Q38388409-16CA5422-09AA-435F-9BA3-3DBBC63CA809Q38664894-B1B59432-14C1-42D2-B197-905606BC6B50Q38681706-2E13AD12-923D-4EE4-9716-C4CB576CD159Q38758287-E0D3A776-B9D1-44CC-8DD7-DA5FF057CCD3Q38848385-8AD58A1C-EDD2-40B5-9D85-464DF67562DBQ39331415-76B13DDE-9FA9-44D7-A81D-2E8F2CA684A5Q39407763-B6A8908B-D947-4920-A957-2813F163F9A4Q39778779-7B486EDA-50A3-4EDE-B4F2-867155620CD6Q42158020-B7EB6C12-7498-4E9F-B0B8-2EF123BFE88EQ43115435-3CE931C8-3C6F-4626-AB32-D9B257CC0130Q45336339-CA14F674-DF41-49B4-B0A3-889A71EECD9DQ46674667-1832DEFD-3AB6-47FB-BECD-0A1091F06D00Q46750199-DF0D61D2-6DC1-4E87-AD5C-B754F376EF1CQ47104987-7C5B72EF-710D-4408-B433-1171880F375DQ47364349-882C0B47-6ADB-4A30-A952-26BC0F5C24D9Q47393480-E4610086-1E94-4560-8B2F-2B2644CC234DQ47838168-ECFE5200-CADD-48AC-91DB-D1B9E794A4B3Q48857966-C01796CD-9EBF-42A6-98E2-9518B5AB5D0FQ83858845-F66CBDCA-EF1D-4DD3-84DF-FEC6BCD66506Q90318958-58281410-7200-46A3-B6CD-5AE18E991E46
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chad D Rethorst
@es
Chad D. Rethorst
@en
Chad D. Rethorst
@nl
Chad D. Rethorst
@sl
type
label
Chad D Rethorst
@es
Chad D. Rethorst
@en
Chad D. Rethorst
@nl
Chad D. Rethorst
@sl
prefLabel
Chad D Rethorst
@es
Chad D. Rethorst
@en
Chad D. Rethorst
@nl
Chad D. Rethorst
@sl
P106
P1153
25223786500
P21
P31
P496
0000-0002-8168-2829
P569
2000-01-01T00:00:00Z